Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% in Demodex Blepharitis: A Systematic Review

Abstract

Description

Demodex blepharitis is a chronic eyelid inflammation caused by Demodex mites, which are ubiquitous skin parasites. Lotilaner, a newly United States Food and Drug Administration (FDA)-approved drug, is an antiparasitic agent that selectively inhibits parasite-specific γ-aminobutyric acid chloride channels, inducing spastic paralysis and death of Demodex mites. It is applied as an ophthalmic solution, 0.25%, twice a day for 6 weeks, and it has a long half-life and high lipophilicity, facilitating the penetration of the drug into the eyelash follicles and meibomian glands where the mites reside. This study systematically reviewed 6 clinical trials that compared lotilaner with placebo for Demodex blepharitis. The primary efficacy endpoint was complete collarette cure, defined as collarette grade 0 on the upper lid of the analysis eye. The secondary efficacy endpoint was decreased mite density with mite eradication, defined as 0 mites per lash on the analysis eye at day 42. The results showed that lotilaner treatment was significantly more effective than the control in achieving both endpoints, with a maximum reduction of 94.7% in mite density at day 43. The treatment effect persisted for at least 2 months after the end of treatment. Lotilaner was also safe and well tolerated, with no serious adverse events reported.

For primary care providers, this study underscores the importance of recognizing collarettes as a key diagnostic marker for Demodex blepharitis during routine examinations. Lotilaner ophthalmic solution, 0.25%, offers a novel, effective therapy for this condition, enabling earlier intervention and improved outcomes for patients. Further investigation in larger trials is warranted to confirm these findings and refine their clinical application.

Background

Blepharitis is a persistent eyelid margin inflammation that manifests as redness, ocular discomfort, irritation, exudate, debris, and eyelash abnormalities. Corneal involvement may occur in more severe cases, such as superficial punctate keratopathy, infiltrates, epithelial defects, or keratitis. Blepharitis can have various causes, including allergic, staphylococcal, and seborrheic, but one of the most frequent causes is Demodex mite infestation.¹

Two main types of Demodex mites live on humans. Demodex folliculorum (0.3 mm to 0.4 mm) mainly inhabits the eyelash base and follicles, causing anterior blepharitis. They consume epithelial cells around the hair follicles, which may also lead to trichiasis (eyelash inversion) or madarosis (eyelash loss). Demodex brevis (0.2 mm to 0.3 mm) prefers the meibomian glands, causing posterior blepharitis. They can obstruct gland openings, impair meibum secretion, and cause meibomian gland dysfunction. Not all patients with Demodex mites have symptoms, which indicate these mites may be part of the normal ocular flora. Demodex mites have been linked to other skin conditions, such as papulopustular rosacea, rosacea-like facial eruptions, and eyelid basal cell carcinomas.²

The Demodex mite is transparent, hairless, and has a spindle/cylindrical shape with rings on its body and 4 short legs on each side of the front part of the body (podosoma). Their short legs limit their movement to only 8 to 16 cm/hour.³ Following fertilization, the adult female mite migrates into the hair follicle or sebaceous gland, where she lays her eggs. The eggs develop through larval and nymphal stages into adults over approximately 7 to 8 days. Once mature, the adult offspring return to the follicular opening, where they remain for an additional 5 days. The whole life cycle is about 15 days, after which the mite bursts and spills its contents to the nearby tissue. The Demodex mite is highly host-dependent and can only survive for a few days outside of it. When demodicosis happens, this can cause symptoms typical of blepharitis, such as ocular discomfort, swollen eyelids, and itching.² Itching, especially along the lid margin, is the main symptom reported in most cases of D. folliculorum. There is a positive link between itching and Demodex, with its presence increasing the chance of having Demodex by 2.5 times. Itching may be partly explained by the over-expression of allergen-coding genes, which may lead to a type I allergic reaction. Tear cytokines, especially interleukin-17, which play a role in ocular surface and lid margin inflammation, are positively linked to demodicosis.³

Epidemiology and Diagnosis

Demodex blepharitis is a highly prevalent condition, with some studies suggesting that it affects up to 84% of patients with chronic blepharitis.¹ The burden of the disease underscores the importance of accurate diagnosis and appropriate treatment. Diagnosis is primarily performed under slit-lamp examination, where the hallmark finding of cylindrical dandruff or “collarettes” around the eyelash base is observed. This examination is crucial and can only be conducted by trained ophthalmologists, making them the primary professionals responsible for diagnosing and treating this condition.

While ophthalmologists are essential in managing Demodex blepharitis, primary care providers (PCPs), internists, and family physicians can play an indirect but vital role. They can screen for symptoms suggestive of blepharitis, educate patients about the importance of eyelid hygiene, and refer patients with refractory or suspicious cases to ophthalmologists for further evaluation and definitive treatment. This multidisciplinary approach ensures timely diagnosis and optimal management.

Treatment Options

Eyelid hygiene, 1% sulfur ointment, 1% mercury oxide ointment, pilocarpine gel, iodized solutions, warm compress, intense pulsed light, ivermectin, and tea tree oil are some of the current treatment options. Tea tree oil therapies have antibacterial, antifungal, and anti-inflammatory effects.² Oral ivermectin treatment can cause moderate-to-severe adverse reactions but are usually transient and mild. Topical ivermectin treatment has primarily mild side effects, such as irritation, allergic dermatitis, and redness. Ivermectin can kill the parasites and reduce the inflammation caused by Demodex infestations.⁴ Studies have shown that oral ivermectin-metronidazole combination therapy is more effective than oral ivermectin alone.⁵ Likewise, topical ivermectin 0.1%-metronidazole 1% gel eliminated Demodex in 96.6% of patients with Demodex blepharitis.⁶ Metronidazole has acaricidal, antiinflammatory, antioxidant, and antibacterial properties through its active metabolites. Adding metronidazole to oral and/or topical ivermectin can enhance the therapeutic effects.

There was a high need for a new therapeutic approach to eliminate this mite with minimal side effects and maximum tolerability. Therefore, lotilaner ophthalmic solution, 0.25%, was developed and showed promising results for treating blepharitis caused by Demodex infestation.

Material and Methods

Protocol

For this systematic review, we used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) for clinical trials.⁷

Eligibility Criteria and Study Selection

We included clinical trials on humans from the last 10 years. We included human clinical trials published in English between January 2014 and December 2023, as identified through an electronic search of PubMed, ClinicalTrials.gov, and the Cochrane Library conducted between August and October 2023. We excluded all animal studies, studies other than clinical trials, and those that did not fulfill the study's outcome. All patients in the studies had blepharitis due to Demodex infestation.

Subsequently, we removed duplicate papers, studies in which the title was not pertinent, and studies with absent results.

After screening these studies, we included papers with the following criteria:

1. Patients: Individuals with blepharitis due to Demodex infestation

2. Intervention: Lotilaner ophthalmic solution 0.25% alone or lotilaner ophthalmic solution 0.25% versus placebo

3. Comparator: Treatment or control group

4. Outcome: collarette cure and mite eradication

Database and Search Strategy

An electronic search of the literature using PubMed, ClinicalTrials.gov, and Cochrane Library was performed from August to October 2023. The search term combination we used was “lotilaner” and “blepharitis.” We used an advanced search strategy with the following terms: (lotilaner [Title/Abstract]) AND (blepharitis [Title/Abstract]). The study selection process is outlined in Figure 1, which presents the PRISMA flow diagram.

Figure 1.

The study results using a Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow chart.

Data Extraction and Analysis

We collected the following information for each study: author and year of publication, methodology, and functional outcomes. Baseline characteristics of the study methods included the number of participants in the treatment group, the number of participants in the control group, and the time of outcome assessment. The primary efficacy endpoint was complete collarette cure, defined as collarette grade zero on the upper lid of the analysis eye. The secondary efficacy endpoint was decreased mite density with mite eradication, defined as 0 mites per lash on the analysis eye at day 42.

Bias Assessment

For assessing bias, we used the Cochrane Collaboration’s tool risk assessment (version 1) of the clinical trials,⁸ and the results are presented in Figure 2.

Figure 2.

The bias analysis of the clinical trials in the systematic review.

Results

In total, 6 randomized clinical trials were included in this systematic review. Four of these trials included a control group, while 2 were single-arm studies without a control group. Despite differences in design, all studies reported baseline characteristics and measurable outcomes. Table 1 presents the characteristics of the included studies, including author, year, country, study design, sample size, dosing regimen, route of administration, and timing of outcome assessment.

Table 1.

Study Characteristics of Included Clinical Trials

Author, year of the publication	Country	Study design	Number of patients in treatment group	Number of patients in control group	Intervention	Time of outcome assessment
Gonzalez-Salinas et al, 2021 (MARS)9	Mexico; USA	Single-arm, open-label, Phase 2a treatment study	15	0	Lotilaner ophthalmic solution, 0.25% twice a day	Days 7, 14, and 28. Days 60 and 90 after treatment cessation
Gonzalez-Salinas et al, 2021 (IO)10	Mexico; USA	Single-arm, open-label, Phase 2a treatment study	18	0	Lotilaner ophthalmic solution, 0.25% twice a day	Days 7, 14, 28, and 42
Gonzalez-Salinas et al, 2022 (JUPITER)11	Mexico; USA	Phase II, randomized, controlled, double-masked clinical trial	30	30	Lotilaner ophthalmic solution, 0.25% vs placebo twice a day	Days 7, 14, and 28. Days 60 and 90 after treatment cessation
Yeu et al, 2022 (EUROPA)12	Mexico; USA	Randomized, controlled, double-masked clinical trial	27	27	Lotilaner ophthalmic solution, 0.25% vs placebo twice a day	Days 7, 14, 28, and 42
Yeu et al, 202313	USA	Prospective, randomized, controlled, double-masked, phase 2b/3 clinical trial	212	209	Lotilaner ophthalmic solution, 0.25% vs placebo twice a day	Days 8, 15, 22, and 43
Gaddie et al, 202314	USA	Prospective, randomized, double-masked, vehicle-controlled phase 3 trial	203	209	Lotilaner ophthalmic solution, 0.25% vs. placebo twice a day	Days 8, 15, 22, and 43

The patient inclusion criteria for the 6 studies were similar, as follows: all 6 studies enrolled adult patients (≥18 years) of both sexes with Demodex blepharitis infestation, defined as infection of at least 1 eye with Demodex mites (≥1.5 mites per lash in upper and lower eyelids), collarettes (grade 2 or worse) in greater than 10 lashes of the upper lid, and mild to severe lid margin erythema. The analysis eye was the one with higher mite density at screening; the right eye was chosen in case of equal density.^9–14

We conducted a systematic review of 6 clinical trials that measured the effects of different interventions on various outcomes. Table 2 summarizes the results of each trial and indicates which outcomes showed statistically significant differences between the intervention and control groups.

Table 2.

Summary of Study Outcomes

Author, year of the publication	Mean mite density	Mite eradication	Mean collarette grade
Gonzalez-Salinas et al, 2021 (MARS)9	Decreased from 2.28 ± 0.16 at baseline to 0.14 ± 0.05 at Day 28 (P < .0001)	On Day 90, mite eradication was observed in 10 of 12 eyes (83.3%) (P < .05)	Improved from 3.07 ± 0.21 at baseline to 1.69 ± 0.24 at Day 14 and 0.79 ± 0.19 at Day 28. From baseline, statistical significance for both upper (P = .0034) and lower (P = .0122) lids at Day 14 and every visit thereafter
Gonzalez-Salinas et al, 2021 (IO)10	Decreased from 2.63 ± 0.39 at baseline to 0.12 ± 0.08 on day 42	By day 42, total mite eradication was achieved in 77.8% of participants and near or total eradication was achieved in 94.4% of eyes	Decreased from 3.56 ± 0.17 at baseline to 0.28 ± 0.11 at day 42
Gonzalez-Salinas et al, 2022 (JUPITER)11	Statistically significant decrease in the study group compared to the control group at Day 28 (P < .002)	Mite eradication was achieved in 66.7% of eyes in the study group at Day 28, compared to 25.9% in the control group (P = .005)	Study group showed a statistically significant decrease compared to the control group beginning at Day 14 (P = .003) and continuing post-treatment through Day 90 (P < .001)
Yeu et al, 2022 (EUROPA)12	The study group demonstrated a statistically significantly greater reduction in mite density compared to the control group by Day 14, 87.0% of the analysis eyes had at least a 50% mite reduction	Mite eradication at Days 28 and 42 was 55.6% and 73.3%, respectively, compared to the control group (P = .006 at Day 28 and P = .003 at Day 42)	Study group showed a significant reduction compared to the control group at Day 14 onward for the upper eyelid and Day 28 onward for the lower eyelid of the analysis eye. At Day 42, all participants demonstrated a 2-grade improvement or better in collarette grade
Yeu et al, 202313	Study group showed a statistically significant lower mite density than the control group at days 15, 22, and 43 (P < .0001). At day 43, 94.7% of the eyes in the study group had mean mite density ≤0.5 mites/lash, compared with 35.8% in the control group	Study group achieved a statistically significantly higher mite eradication than the control group at all visits from day 15 through day 43 (P < .0001)	Study group demonstrated a statistically significantly improved (P < .0001) collarette grade compared to the control group from day 8 onward. At day 43, 92.8% of patients in the study group demonstrated at least a 1-grade collarette improvement in the upper eyelid of the analysis eye (P < .0001)
Gaddie et al, 202314	Study group had a much lower (P < .0001) mite density than the control group. On day 43, most of the eyes (86.5%) in the study group had a mean mite density of ≤0.5 mites/lash, compared with only a third (34.7%) in the control group (P < .0001)	Study group patients achieving mite eradication was statistically significantly higher than in the control group at all visits (day 15 onward; P < .0001). On day 43, 51.8% of the patients in the study group achieved mite eradication, compared with 14.6% of patients in the control group (P < .0001)	Study group showed a statistically significant difference (P < .05) as early as day 8 and highly significant (P < .0001) from day 15 onward. On day 43, 96.4% of patients in the study group showed at least a 1-grade collarette improvement in the upper eyelid of the analysis eye (P < .0001)

Collarettes were graded for each eyelid using the grading scale shown in Figure 3. Mite eradication was defined as a mite density of 0 mites/lash. The collarette grading scale for Demodex blepharitis is a nonlinear scale that ranges from 0 to 4:

Figure 3.

A clinical presentation of Demodex blepharitis: grading scale (non-linear) used for collarettes grading in each eyelid.¹³

• Grade 0: 0–2 lashes per eyelid with collarettes.

• Grade 1: 3–10 lashes per eyelid with collarettes.

• Grade 2: More than 10 but less than one-third of lashes per eyelid with collarettes.

• Grade 3: At least one-third but less than two-thirds of lashes per eyelid with collarettes.

• Grade 4: At least two-thirds of lashes per eyelid with collarettes.

A collarette grade of 0 is considered a “collarette cure.” A reduction in collarettes to 10 lashes or fewer (grade 0 or 1) is considered clinically meaningful, while a poor outcome would involve persistent collarette grades of 2 or higher, indicating significant debris and inflammation.

Limitations of the Clinical Trials

Table 1 shows that the first 2 studies by Gonzalez-Salinas et al (2021) were single-arm pilot studies with small sample sizes.^9–10 Furthermore, 1 of them recruited patients from the placebo group of a previous study, and the sample size calculation was based on clinical and practical considerations rather than statistical power. The rest of the studies were randomized controlled trials with double masking. Gonzalez-Salinas et al (2022) acknowledged a limitation of not including subjective symptoms as an inclusion criterion or an outcome measure since their study focused on Demodex eradication and signs improvement rather than symptom improvement.¹¹ Yeu et al (2022) reported limitations of small sample size and loss of follow-up visits, likely due to the COVID-19 pandemic at the time of this study.¹² To address the issue of dropout reported in their previous study, Yeu et al (2023) increased the sample size and performed a power analysis based on the response rates observed in previous clinical studies.¹³ A limitation of the study by Gaddie et al (2023) was the need for long-term follow-up of recurrence since Demodex mites could reinfest the eyelids from other areas of the face. In addition, they used collarette and erythema grading scales that had not been validated for reliability, which were also used in previous studies.¹⁴

Discussion

Demodex blepharitis is a highly prevalent condition, with reported rates ranging up to 84% among patients with chronic blepharitis. For PCPs, recognizing this condition is crucial, as many patients may initially present with nonspecific ocular symptoms, such as itching, lid margin erythema, and eyelash abnormalities. Although definitive diagnosis requires slit-lamp examination by an ophthalmologist, PCPs are well-positioned to play a key role in identifying potential cases and initiating referrals. Collarettes, the cylindrical dandruff at the base of eyelashes, are a hallmark of Demodex infestation and can serve as a practical marker for PCPs to suspect the condition during routine examinations, especially in patients with recurrent symptoms unresponsive to conventional treatments. Additionally, PCPs can educate patients on the importance of eyelid hygiene as a preventive and maintenance measure, potentially improving outcomes.

Efficacy of Lotilaner Ophthalmic Solution, 0.25%

Demodex mites live in human hair follicles, especially on the cheeks, nose, eyebrows, eyelashes, and forehead. Demodex infestation becomes more common with age, as the skin becomes drier and the fat decreases, which makes the Demodex move toward the only place with moisture and oil, the meibomian gland on the eyelid margin. Among the 6 studies included in this review, 2—MARS and JUPITER—were multicenter clinical trials specifically evaluating lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis. The MARS study was a pilot trial that first assessed the safety and efficacy of lotilaner in a small patient population, providing preliminary evidence for its potential therapeutic benefit.⁹ Building on these findings, the JUPITER study was a larger, randomized, controlled, double-masked clinical trial that further validated lotilaner’s efficacy and safety profile in a broader cohort.¹¹ Both studies employed a 4-week treatment duration. In contrast, the remaining four studies included in this review administered lotilaner over a 6-week period.^10,12–14 Given that the life cycle of the Demodex mite, from egg to adult, spans approximately 3 weeks, a 6-week treatment duration may offer improved efficacy by covering two full life cycles, thereby enhancing the likelihood of complete mite eradication before reproduction recurs.

Lotilaner ophthalmic solution, 0.25%, exhibited potent anti-Demodex activity in all 6 studies, achieving statistically significant reductions in mite density, complete mite eradication, and improvements in collarette grade. Collarette grade, a key indicator of Demodex infestation, improved significantly for both upper and lower eyelid margins as early as 8 days after treatment initiation in the studies by Yeu et al (2023) and Gaddie et al (2023).^13,14 In the analysis for all 6 studies, the mean eye mite density in the lotilaner group was significantly lower than that in the control group on Day 14, and all subsequent follow-up visits, reaching a maximum reduction of 94.7% at day 43 in the study by Yeu et al (2023).¹³

The ultimate goal of treating Demodex blepharitis is to eradicate mites, the underlying cause of the condition, rather than just eliminating collarettes, the characteristic sign of the condition. Mite eradication, defined as 0 mites per lash in the analysis eye, was achieved by at least 50% of the lotilaner group at 28 days of treatment and maintained for 2 months after treatment discontinuation in the MARS and JUPITER studies.^9,11 Three studies also reported a composite cure outcome, which combined collarette and erythema grades (both grade 0 on day 43 for the upper eyelid of the analysis eye). Yeu et al (2022) found a significantly higher composite cure rate in the lotilaner group than in the control group (73.3% vs. 10.5%; P < .001) after 42 days of treatment.¹² Yeu et al (2023) reported that 67.5% of the lotilaner group achieved a clinically meaningful composite cure, and nearly half had a 1 grade reduction in erythema after 43 days of treatment.¹³ Gaddie et al also showed a significantly higher composite cure rate in the lotilaner group compared with the control group (19.2% vs. 4.0%; P < .0001) on day 43.¹⁴ The last 2 studies noted that lid erythema resolution lagged behind mite and collarette elimination and that erythema cure peaked at later time points. This suggests that inflammation may take longer to subside after mites and collarettes have been cleared or resolved.

The resolution of collarettes was closely followed by the eradication of mites, confirming the causal link between Demodex infestation and this key sign. Since mite density and collarettes are strongly correlated, slit-lamp examination of the upper eyelid margin for collarettes is a simple and feasible method for detecting mite infestation and monitoring treatment response in routine clinical practice. In the study by Gaddie et al, the patients did not use mechanical lid scrubbing or other lid therapies, indicating that lotilaner alone, rather than any mechanical cleaning of the lid margin, was responsible for mite eradication.¹⁴

Lotilaner ophthalmic solution, 0.25%, is a novel drug targeting Demodex blepharitis’s root cause. The clinical trials showed that lotilaner ophthalmic solution, 0.25%, applied twice daily for 43 days, was superior to the vehicle control in treating Demodex blepharitis. This new United States Food and Drug Administration-approved treatment offers a promising option for resolving this challenging condition.

For PCPs, the correlation between collarette resolution and mite eradication is particularly significant. Collarettes are visible without specialized equipment, making them a practical tool for PCPs to monitor treatment response and guide follow-up referrals where necessary.

Safety of Lotilaner Ophthalmic Solution, 0.25%

For all 6 studies, the safety of the treatments was evaluated by monitoring the occurrence of adverse events related to the interventions, changes in corrected distance visual acuity (CDVA), intraocular pressure (IOP), and slit-lamp examination findings (to assess the presence and severity of any eyelid, corneal, conjunctival, or anterior chamber abnormalities, and lens pathology and corneal fluorescein staining) at each visit. Gaddie et al (2023) also performed hematologic, blood chemistry, and urinalysis tests.¹⁴ Corrected distance visual acuity was measured using either the participant’s glasses or a pinhole occluder, with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a distance of 4 meters, and was recorded as logMAR. A change of more than 2 lines on the ETDRS chart (>0.2 logMAR) was considered clinically meaningful. Intraocular pressure was assessed using applanation tonometry. Staining in each of the 5 areas of the cornea was graded based on the National Eye Institute scale. The most common treatment for Demodex blepharitis is lid hygiene products containing tea tree oil (TTO) or its most active ingredient that kills mites, terpinen-4-ol (T4O). However, the effectiveness of TTO-based products in treating Demodex blepharitis remains inconclusive. A Cochrane systematic review reported limited and low-certainty evidence supporting TTO’s efficacy, and highlighted concerns regarding its potential to cause ocular irritation and periocular skin inflammation. Additionally, TTO has been shown to damage epithelial cells and fibroblasts, which are essential for tissue repair and wound healing.² Moreover, it has been shown to harm human meibomian gland cells, which produce the oily layer of the tear film. Both Gonzalez-Salinas et al (2021) studies reported no adverse events associated with the use of lotilaner ophthalmic solution 0.25%, no significant changes in CDVA, IOP, or slit-lamp biomicroscopy findings, and no patients who discontinued the treatment due to intolerance to the medication.^9,10 The other 4 studies assessed eye drop comfort using a scale ranging from very comfortable to very uncomfortable. The comfort level of the eye drops was measured on days 7, 14, and 28. Gonzalez-Salinas et al (2022) reported no serious adverse events, minimal or no change in mean CDVA and IOP, and no significant changes in slit-lamp examination findings. Also, no participants in either the control or study group rated the study medication as “very uncomfortable” at any time during the treatment period.¹¹ Yeu et al (2022) found no significant difference in the comfort level of the eye drops between the study and control group (P = .999) and reported no serious adverse effects or treatment discontinuation.¹² The mean CDVA and IOP remained stable from baseline to day 42. Most participants rated the drops as comfortable or neutral, and treatment did not cause any reduction in visual acuity or corneal epithelial damage. Similarly, Yeu et al (2023) found no significant difference in the subjective comfort of the eye drops between the study and vehicle control groups.¹³ The adverse effects in the study group were mild, the most common being pain at the instillation site. The patients rated the eye drops as very comfortable throughout the study. However, 1 patient in the study group developed mild upper and lower eyelid swelling and was instructed to stop the treatment. Gaddie et al (2023) reported that pain at the instillation site was the most common adverse event related to the study drug.¹⁴ Otherwise, no over-serious adverse effect was observed. In the study or control groups, the median values for systemic laboratory tests (blood, blood chemistry, and urine analysis) did not change significantly from baseline to day 43.

The results show that lotilaner treatment was well-tolerated by the patients. The comfort and tolerability of the eye drops are crucial for patient compliance and treatment outcomes. The medication was a topical ophthalmic solution with a lower viscosity than a gel or ointment. Lotilaner ophthalmic solution, 0.25%, was safe and acceptable for the patients.

Future Approach

The effect of lotilaner therapy on objective measures of lid and conjunctival redness and lid and tear film inflammation is an exciting topic for future research. Future controlled studies with a more significant number of eyes should also continue to assess the tolerability of the medication. The optimal duration of treatment for Demodex blepharitis remains uncertain, although significant improvements were seen as early as 14 days. Moreover, longer-term follow-up of 6–12 months in future studies would be helpful to determine the recurrence rate of collarettes and mites.

To improve accessibility, future research should prioritize the development of simpler and more accessible screening tools or diagnostic criteria that can be used by PCPs. This could empower PCPs to recognize key symptoms, initiate timely referrals, and support long-term management, thereby significantly improving outcomes for patients with Demodex blepharitis.

Additionally, updates from ongoing trials may provide new evidence to strengthen the current understanding of lotilaner’s potential and refine clinical practices for its use.

Study Limitations

The limited number of clinical trials that met our inclusion criteria reflects the novelty of lotilaner as a therapeutic option. As a result, the current findings may only partially capture its full potential. Another significant limitation is the variability in treatment durations across studies; 2 of the 6 studies included in this review lasted only 4 weeks instead of the recommended 6 weeks. This inconsistency may affect the ability to predict clinically relevant outcomes, even if the correlations observed were statistically significant.

Furthermore, the reliance on slit-lamp examinations by ophthalmologists for diagnosis limits accessibility and highlights the need for simpler diagnostic tools suitable for use by PCPs. This is particularly important to enable earlier detection and intervention in primary care settings.

Additionally, there is a lack of long-term data on the safety, efficacy, and recurrence rates associated with lotilaner therapy. Data beyond the study durations are critical for understanding the sustained impact of the treatment.

Future multicenter trials, involving larger, more diverse populations, and extended follow-up periods are necessary to validate these findings. Addressing these limitations will enable a more comprehensive understanding of lotilaner’s role in managing Demodex blepharitis and enhance its applicability in broader clinical contexts.

Conclusion

This study evaluated the safety and efficacy of lotilaner ophthalmic solution, 0.25%, a novel drug targeting the root cause of Demodex blepharitis, a chronic eyelid condition that previously had no FDA-approved treatments. Patients who applied the drug twice daily for 43 days had significantly better outcomes than those in the control group. The drug reduced the severity of collarettes, decreased mite density, and demonstrated a treatment effect lasting at least 2 months post-treatment. Furthermore, the drug was well tolerated, with no serious adverse events reported.

This study suggests that lotilaner ophthalmic solution, 0.25%, is a promising therapy for Demodex blepharitis and warrants further investigation in more extensive trials. For PCPs, these findings highlight an opportunity to integrate this therapy into practice by identifying potential cases early through visible symptoms, such as collarettes, and initiating timely referrals. Empowering PCPs with knowledge of this novel treatment can improve access to care and enhance outcomes for patients with Demodex blepharitis.

Funding Statement

This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare-affiliated entity.